Michael T Lu1, Vineet K Raghu1, Thomas Mayrhofer2, Hugo J W L Aerts3, Udo Hoffmann1. 1. Massachusetts General Hospital Cardiovascular Imaging Research Center, Brigham and Women's Hospital Program for Artificial Intelligence in Medicine, and Harvard Medical School, Boston, Massachusetts (M.T.L., V.K.R., U.H.). 2. Harvard Medical School, Boston, Massachusetts,and Stralsund University of Applied Sciences, Stralsund, Germany (T.M.). 3. Brigham and Women's Hospital Program for Artificial Intelligence in Medicine, Massachusetts General Hospital Cardiovascular Imaging Research Center, and Harvard Medical School, Boston, Massachusetts (H.J.A.).
Abstract
BACKGROUND: Lung cancer screening with chest computed tomography (CT) reduces lung cancer death. Centers for Medicare & Medicaid Services (CMS) eligibility criteria for lung cancer screening with CT require detailed smoking information and miss many incident lung cancers. An automated deep-learning approach based on chest radiograph images may identify more smokers at high risk for lung cancer who could benefit from screening with CT. OBJECTIVE: To develop and validate a convolutional neural network (CXR-LC) that predicts long-term incident lung cancer using data commonly available in the electronic medical record (EMR) (chest radiograph, age, sex, and whether currently smoking). DESIGN: Risk prediction study. SETTING: U.S. lung cancer screening trials. PARTICIPANTS: The CXR-LC model was developed in the PLCO (Prostate, Lung, Colorectal, and Ovarian) Cancer Screening Trial (n = 41 856). The final CXR-LC model was validated in additional PLCO smokers (n = 5615, 12-year follow-up) and NLST (National Lung Screening Trial) heavy smokers (n = 5493, 6-year follow-up). Results are reported for validation data sets only. MEASUREMENTS: Up to 12-year lung cancer incidence predicted by CXR-LC. RESULTS: The CXR-LC model had better discrimination (area under the receiver-operating characteristic curve [AUC]) for incident lung cancer than CMS eligibility (PLCO AUC, 0.755 vs. 0.634; P < 0.001). The CXR-LC model's performance was similar to that of PLCOM2012, a state-of-the-art risk score with 11 inputs, in both the PLCO data set (CXR-LC AUC of 0.755 vs. PLCOM2012 AUC of 0.751) and the NLST data set (0.659 vs. 0.650). When compared in equal-sized screening populations, CXR-LC was more sensitive than CMS eligibility in the PLCO data set (74.9% vs. 63.8%; P = 0.012) and missed 30.7% fewer incident lung cancers. On decision curve analysis, CXR-LC had higher net benefit than CMS eligibility and similar benefit to PLCOM2012. LIMITATION: Validation in lung cancer screening trials and not a clinical setting. CONCLUSION: The CXR-LC model identified smokers at high risk for incident lung cancer, beyond CMS eligibility and using information commonly available in the EMR. PRIMARY FUNDING SOURCE: None.
BACKGROUND: Lung cancer screening with chest computed tomography (CT) reduces lung cancer death. Centers for Medicare & Medicaid Services (CMS) eligibility criteria for lung cancer screening with CT require detailed smoking information and miss many incident lung cancers. An automated deep-learning approach based on chest radiograph images may identify more smokers at high risk for lung cancer who could benefit from screening with CT. OBJECTIVE: To develop and validate a convolutional neural network (CXR-LC) that predicts long-term incident lung cancer using data commonly available in the electronic medical record (EMR) (chest radiograph, age, sex, and whether currently smoking). DESIGN: Risk prediction study. SETTING: U.S. lung cancer screening trials. PARTICIPANTS: The CXR-LC model was developed in the PLCO (Prostate, Lung, Colorectal, and Ovarian) Cancer Screening Trial (n = 41 856). The final CXR-LC model was validated in additional PLCO smokers (n = 5615, 12-year follow-up) and NLST (National Lung Screening Trial) heavy smokers (n = 5493, 6-year follow-up). Results are reported for validation data sets only. MEASUREMENTS: Up to 12-year lung cancer incidence predicted by CXR-LC. RESULTS: The CXR-LC model had better discrimination (area under the receiver-operating characteristic curve [AUC]) for incident lung cancer than CMS eligibility (PLCO AUC, 0.755 vs. 0.634; P < 0.001). The CXR-LC model's performance was similar to that of PLCOM2012, a state-of-the-art risk score with 11 inputs, in both the PLCO data set (CXR-LC AUC of 0.755 vs. PLCOM2012 AUC of 0.751) and the NLST data set (0.659 vs. 0.650). When compared in equal-sized screening populations, CXR-LC was more sensitive than CMS eligibility in the PLCO data set (74.9% vs. 63.8%; P = 0.012) and missed 30.7% fewer incident lung cancers. On decision curve analysis, CXR-LC had higher net benefit than CMS eligibility and similar benefit to PLCOM2012. LIMITATION: Validation in lung cancer screening trials and not a clinical setting. CONCLUSION: The CXR-LC model identified smokers at high risk for incident lung cancer, beyond CMS eligibility and using information commonly available in the EMR. PRIMARY FUNDING SOURCE: None.
Authors: Stephen P Fortmann; Steffani R Bailey; Neon B Brooks; Brian Hitsman; Sarah Stuart Rittner; Suzanne E Gillespie; Christian Nissen Hill; Michael C Leo; Phillip M Crawford; Weiming Hu; Dana S King; Conall O'Cleirigh; Jon Puro; Mary Ann McBurnie Journal: Health Serv Res Date: 2020-01-13 Impact factor: 3.402
Authors: Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks Journal: N Engl J Med Date: 2011-06-29 Impact factor: 91.245
Authors: Martin Carl Tammemagi; Matthew T Freedman; Paul F Pinsky; Martin M Oken; Ping Hu; Thomas L Riley; Lawrence R Ragard; Christine D Berg; Philip C Prorok Journal: J Thorac Oncol Date: 2009-06 Impact factor: 15.609
Authors: Olaide Y Raji; Stephen W Duffy; Olorunshola F Agbaje; Stuart G Baker; David C Christiani; Adrian Cassidy; John K Field Journal: Ann Intern Med Date: 2012-08-21 Impact factor: 25.391
Authors: Melinda C Aldrich; Sarah F Mercaldo; Kim L Sandler; William J Blot; Eric L Grogan; Jeffrey D Blume Journal: JAMA Oncol Date: 2019-09-01 Impact factor: 31.777
Authors: Martin C Tammemägi; Timothy R Church; William G Hocking; Gerard A Silvestri; Paul A Kvale; Thomas L Riley; John Commins; Christine D Berg Journal: PLoS Med Date: 2014-12-02 Impact factor: 11.069
Authors: Martin C Tammemägi; Kevin Ten Haaf; Iakovos Toumazis; Chung Yin Kong; Summer S Han; Jihyoun Jeon; John Commins; Thomas Riley; Rafael Meza Journal: JAMA Netw Open Date: 2019-03-01
Authors: Donna K Arnett; Ramachandran S Vasan; Matthew Nayor; Li Shen; Gary M Hunninghake; Peter Kochunov; R Graham Barr; David A Bluemke; Ulrich Broeckel; Peter Caravan; Susan Cheng; Paul S de Vries; Udo Hoffmann; Márton Kolossváry; Huiqing Li; James Luo; Elizabeth M McNally; George Thanassoulis Journal: Circ Cardiovasc Imaging Date: 2021-08-13 Impact factor: 8.589